STUDY SEARCH RESULTS

1 study found for your search request:  3475-667

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults with Classical Hodgkin L...
Condition: Hodgkin Lymphoma
Minimum Age: 3 years, Maximum Age: 25 years
Gender: All
Study ID: NCT03407144
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site